Skip to main content
Premium Trial:

Request an Annual Quote

FTC Clears Millennium Acquisition of COR

NEW YORK, Jan. 18 - Federal regulators have cleared Millennium Pharmaceuticals' proposed acquisition of COR Therapeutics, the companies announced on Friday.

The US Federal Trade Commission has ended the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on Jan. 14, giving the deal the green light.

The deal, which remains subject to a variety of customary closing conditions, will be voted on by shareholders from both firms on Feb. 12, the firms said.

As GenomeWeb reported, Millennium and COR announced their plans to merge on Dec. 6 in a deal that calls for Millennium to trade 0.9873 of its shares for each COR share and to issue a total of 58 million shares to COR shareholders.


When the deal was announced, it was worth an estimated $2 billion, and was the biggest proposed acquisition ever in the biotechnology industry. It was easily overshadowed by the proposed acquisition of Immunex by Amgen, announced late last year and valued at $16 billion in cash.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.